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Background: To elucidate the genetic basis of a novel neurodegenerative disorder in an Old Order Amish pedigree
by combining homozygosity mapping with exome sequencing.
Methods and results: We identified four individuals with an autosomal recessive condition affecting the central
nervous system (CNS). Neuroimaging studies identified progressive global CNS tissue loss presenting early in life,
associated with microcephaly, seizures, and psychomotor retardation; based on this, we named the condition
Autosomal Recessive Cerebral Atrophy (ARCA). Using two unbiased genetic approaches, homozygosity mapping
and exome sequencing, we narrowed the candidate region to chromosome 11q and identified the c.995C > T
(p.Thr332Met) mutation in the TMPRSS4 gene. Sanger sequencing of additional relatives confirmed that the
c.995C > T genotype segregates with the ARCA phenotype. Residue Thr332 is conserved across species and
among various ethnic groups. The mutation is predicted to be deleterious, most likely due to a protein structure
alteration as demonstrated with protein modelling.
Conclusions: This novel disease is the first to demonstrate a neurological role for a transmembrane serine
proteases family member. This study demonstrates a proof-of-concept whereby combining exome sequencing
with homozygosity mapping can find the genetic cause of a rare disease and acquire better understanding of a
poorly described protein in human development.
Keywords: Autosomal recessive cerebral atrophy (ARCA) syndrome, Neurodegeneration, Trypsin-like serine
protease, Homozygosity, Microarray, Exome sequencing, Autosomal recessive inheritance, Old Order AmishBackground
Neurodegenerative disorders can be defined as disorders
with progressive deterioration of neurological functions
such as loss of vision, hearing, and motor function along
with previously attained skills [1]. Such degeneration is
frequently associated with seizures, feeding issues and
intellectual impairment. Neurodegenerative disorders can
be etiologically classified under acquired and inherited
causes [1]. Acquired causes are most common, and
include chronic viral infections, toxin deposition such as
heavy metal ingestion and cancer chemotherapy, and drug
metabolites [2]. Inherited causes can be due to specific
genetic and metabolic defects, such as Rett syndrome,* Correspondence: hegele@robarts.ca
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reproduction in any medium, provided the ormitochondrial disorders such as MELAS, toxin-generating
defects such as PKU, Wilson disease and Hallervorden-
Spatz syndrome, lysosomal storage diseases such as
Niemann-Pick (types A and C) and Gaucher disease, and
leukodystrophies such as Alexander disease [2].
Neurodegeneration in these disorders can involve both
the grey and white matter of the brain and spinal cord.
Injury of grey matter is irreversible and manifests as sei-
zures, psychomotor retardation, visual impairment and
extrapyramidal disturbances such as akathisia (inability
to remain motionless) [2]. On the other hand white-
matter, mainly represented by myelinated axons, involves
disease that is dominated by motor difficulties and
chronic encephalopathy [2].
Herein we describe a novel neurodegenerative disorder
affecting four infants in a highly consanguineous Amish
pedigree. Using homozygosity mapping and exome
sequencing, we identified a mutation in TMPRSS4, atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is poorly understood. This work exemplifies the use of
unbiased approaches to find novel proteins implicated in
rare single-gene disorders.
Materials and methods
This study had ethics approval by the Office of Research
Ethics at the University of Western Ontario (number
07920E). Four participating families from an Old Order
Amish community in Ontario provided informed con-
sent and received no financial compensation. All four
probands had thorough clinical evaluations, including
MRI-head scans. In addition, an autopsy of one proband
(V-9) was completed. The pedigrees of the families were
assembled through interviews and local Amish com-
munity records. In addition, DNA from umbilical cord
blood and buccal swabs were extracted from 208 ARCA-
unaffected individuals from the Old Order Amish com-
munity to determine mutant allele frequency.
Genomic DNA of peripheral blood from 3 affected
(V-10, V-12, V-14) and 5 unaffected (V-6, V-8, IV-8,
V-15, IV-12) parents and siblings were genotyped
using Genome-Wide Human SNP Array 6.0 at London
Regional Genomics Centre (http://www.lrgc.ca). Geno-
types were called using Affymetrix Genotyping Console,
with quality control thresholds for subject call rate
(>90%), SNP call rate (95%), Hardy-Weinberg equili-
brium (P > 0.0001) and minor allele frequency (>1%).
Due to the consanguineous nature of the pedigree,
family-based autozygosity or homozygosity mapping
was performed using Agilent GT v2.0 software to scan
the genotyped SNPs for runs of homozygous blocks.
The location scores for each of these homozygous
blocks were calculated within Agilent GT v2.0. While a
few homozygous block were seen, the one on chromo-
some 11q clearly had the highest location score and this
block was considered to most likely harbour the disease
gene [3].
For exome sequencing, targeted enrichment and se-
quencing were performed on DNA extracted from the
peripheral blood of individuals V-10 and V-12, both
with typical features of ARCA. Exome enrichment was
performed with Agilent SureSelect Human All Exon
50 MB Kit at The Centre for Applied Genomics (http://
www.tcag.ca). Paired-end sequencing was performed on
Illumina GAII generating 100-bp reads, which were
subsequently aligned to the human reference genome
sequence (hg19/ GRCh37), using NextGENe software
and CLC-Bio Workbench.
TMPRSS4 in the linked region on chromosome 11q
was first screened by Sanger sequencing in an affected
individual, a parent, an unaffected sibling, and a non-
Amish control. Co-segregation of the TMPRSS4 variation
with disease was demonstrated with direct sequenceanalysis in a total of 18 family members, including the
affected individuals. TaqMan assays were used for iden-
tifying allele frequency of the TMPRSS4 variation in
exon 10, c.995C > T (GI:145701031), within 208 Old
Order Amish controls and 2382 ethnically diverse and
healthy non-Amish controls. TaqMan quantitative real-
time PCR assays provided allele discrimination using
two allele-specific TaqMan probes synthesized for
detecting the TMPRSS4 variation (allele C: 5′ VIC-CTG
CTT CGT AAA GCC and mutant allele A: 5′ FAM-
CTG CTT CAT AAA GCC).
Conservation of the TMPRSS4 protein across species
was determined with ClustalW, a multiple-sequence-
alignment computer program [4]. Impact of the amino
acid mutation on TMPRSS4 protein structure, function,
and pathological implication was predicted with four
online tools, namely PolyPhen-2, Panther, SNPs3D, and
PMUT.
Results
Clinical characterization of autosomal recessive cerebral
atrophy (ARCA)
Four affected children were identified in an Old Order
Amish pedigree (Figure 1) to have similar clinical fea-
tures and subsequently a thorough clinical evaluation
was performed on them (Table 1).
V-9, born in 2004, was the product of an uncompli-
cated pregnancy and delivery at 36.5 weeks gestation,
with a head circumference of 30 cm (<3rd percentile).
Her neonatal period was unremarkable until 6 weeks of
age, when the infant refused to suck. By 3 months of
age, she had frequent reflux, was agitated during feeds
and was generally irritable. By 7 months of age, she had
regressed such that she was unable to smile or laugh, to
rollover or sit-up unsupported, and could neither ‘babble’
nor ‘coo’. Growth charts demonstrated progressive micro-
cephaly with head circumference at <3rd percentile at 6.5
months of age. Musculoskeletal examinations demon-
strated spasticity (fisted hands and leg scissoring), abnor-
mal tone and constant akathisia with no notable seizure
activity. Visual impairment was suggested since she was
unable to follow objects by 1 year of age. Investigations
ruled out known inborn errors of metabolism and mito-
chondrial disorders. Of note she had abnormal blood
work of unknown significance demonstrating elevated am-
monia, manganese, lactate, and platelets levels. MRI and
CT scans revealed severe diffuse loss of cerebral volume
with symmetrical enlargement of ventricular space, af-
fected grey and white matter with a thinned corpus
callosum, however, the cerebellum, brainstem and mid-
brain were spared. Eventually, she was placed in palliative
care since she was unable to swallow or drink independ-
ently. She died at 18 months most likely due to failure to
thrive, with no follow-up autopsy.
Figure 1 Old Order Amish pedigree with consanguinity (indicated by the double lines) has four individuals with ARCA, a disease with
an autosomal-recessive mode of inheritance. Affected individuals are shown as blackened squares (male) and circles (female). Diagonal lines
across symbols indicate deceased individuals.
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following a normal pregnancy and delivery. Once again,
the infant was developing appropriately until 3 months of
age when she stopped gaining weight, stopped smiling,
was unable to ‘coo’ nor roll over. Suckling regressed by
5 months of age and she had a G-tube insertion by one
year of age. Her family doctor noted microcephaly with no
head growth post 6 weeks of birth and premature anterior
fontanelle closure. At 2 years of age, her head circum-
ference was recorded at 35.5 cm (<3rd percentile). By
6 months of age she developed seizures described to cause
head deviation, ipsilateral arm extension, lip biting and a
high-pitched scream followed by a brief period of sleep
and then arousal. Interestingly, EEG performed at
9 months demonstrated no epileptiform activity. These
seizure-like episodes increased in frequency by 15 months
of age such that she was placed on a palliative seizure
therapy regimen. She also had arm stiffness and leg
scissoring indicating spasticity, akathisia, brisk reflexes
and hypotonic lower extremities. In addition, she was irri-
table and startled easily. Investigations ruled out MELAS,
inborn errors of metabolism and Hallervorden-Spatz syn-
drome, and muscle biopsies were normal. MRI demon-
strated enlarged lateral and 3rd ventricles with marked
atrophy of cortical tissue, sparing the pons and cerebellum
(Figure 2A). The infant died at 2 years of age. Although
autopsy was unable to prove cause of death, it was con-
cluded that the seizures were not severe enough to cause
cortical degeneration. Gross evaluation of brain revealed a
pale thalami, normal occipital region, brainstem, and
cerebellum as well as symmetrical atrophy of cerebral hemi-
spheres. Microscopic evaluation of the brain demonstratedunaffected brain stem and meninges, material depo-
sition in neurons, like calcium, as well as severe loss of
myelin in white matter. The rest of the organs were un-
remarkable on autopsy.
V-12 was born at 39 weeks gestation in 2001 following
an uncomplicated pregnancy and delivery. He had a rela-
tively unremarkable neonatal period except that his
parents noted him to have constant akathisia only while
awake. He was microcephalic since 3 months of age and
was recorded to have a premature anterior fontanelle clo-
sure with a head circumference measurement of 43.3 cm
at 4 years of age (<3rd percentile). Regression of develop-
mental milestones began within 1 month of age when he
stopped smiling, had exaggerated startle response by
3 months; at 4.5 years he was able to kick some toys and
bat at objects, but could neither speak nor gesture. He
had a diagnosis of cortical visual impairment with atrophic
optic fundi and nystagmus by 2 years of age. By 3 months
of age, he began having episodes of repetitive extension of
arms and hands associated with stiffening of the body with
a shriek-like cry with EEG findings of generalized epilepti-
form activity. By 4 years of age, he was prescribed monthly
botox injections and daily oral baclofen, and was wheel-
chair bound due to the spasms and abnormal increased
muscle tone, which began by 11 months of age. He also
had a G-tube insertion to prevent his recurrent aspiration
pneumonitis episodes. Investigations ruled out known
inborn errors of metabolism and MELAS. Blood work
demonstrated elevated manganese, lactate, and platelet
levels. Imaging consistently showed cerebral atrophy and
ventriculomegaly with subtle atrophy of brainstem and
corpus callosum. At 12 years of age, he continues to live
Table 1 Clinical description of the four ARCA-affected individuals
Affected individuals (year of birth)
V-9 (2004) V-10 (2000) V-12 (2001) V-14 (1999)
Karyotype 46, XX 46, XX 46, XY 46, XY
Pregnancy
and delivery





36.5 weeks 38 weeks 39 weeks 39 weeks
Weight at
birth




47.5 cm (25th percentile) N/A N/A N/A
HC, at birth* 30 cm (<3rd percentile) N/A N/A N/A
Fontanelle
closure
at 6.5 mo: Anterior open (N),
posterior closed (N)






Status died at 18 months died at 2 years alive at 12 yrs alive at 14 yrs
Autopsy - + - -
Development
milestones
Suckling stopped by 6 weeks stopped by 5 mo N/A N/A
Smile started at 2 mo, stopped by
7 mo
Started at 2 mo, stopped by 3 mo no reflexive smile at 1 mo Started at 2
mo, stopped
by 4 mo
Sitting unable at 7 mo unable at 8 mo unable at 4 yrs unable at 5 yrs





- + + +
EEG N/A marked abnormality with low










Spasticity + (fisted hands, legs scissoring) + (legs scissoring, arms stiff) + (myoclonic spasm due
to sound/light touch, fisted
hands)
+ (clonus of R
ankle)
Reflexes N/A brisk, clonus of L ankle unable to assess hyperreflexia
Tone hypotonic trunk, hypertonic
extremities








36.5 cm @ 6.5 mo (<3rd
percentile)
35.5 cm @ 2 yrs (<3rd percentile) 43.3 cm @ 4 yrs (<3rd
percentile)
39 cm at 8.5
mo (<3rd
percentile)
Akathisia + + ++ (while awake) ++















Fundoscopy N/A N/A mild atrophic fundi hypoplastic
optic nerve
and fovea
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Table 1 Clinical description of the four ARCA-affected individuals (Continued)
Hearing Normal normal normal normal





Elevated ammonia, Mn, lactate,
platelets





MRI Age at time of
imaging
10 mo 8 mo, 11 mo, 3 mo, 12 mo 7 mo, 13 mo,
6 yrs 7 mo
Description Severe symmetrical cerebral
volume loss, gray and white
matter affected, thinned corpus
callosum. Cerebellum,
brainstem, midbrain and
supratentorial deep grey matter
are unaffected.
Enlarged lateral and 3rd ventricles,
severe uniform atrophy of the
brain with subcortical white matter










CT Age at time of
imaging
6 mo 3 mo










* Based on: Barbier et al, 2013. Pediatrics. “New Reference curves for Head Circumference at Birth, by GA”. Abbreviations: N/A, not available; "-", not determined.
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his seizures are better controlled seizures and he is less
irritable.
V-14 was the first known proband with ARCA in this
pedigree born in 1999. He was a product of a clomid-
induced twin pregnancy with a fraternal sister who
continues to have normal development. Delivery was in-
duced at 39 weeks with a birth weight of 2550 grams (<3rd
percentile). His neonatal period was unremarkable overall.
He was microcephalic prior to development regressions,
which were first noted after 4 months of age. By 4 months
he stopped smiling, laughing, cooing, and had abnormal
tone. By 9 months of age, he would be easily startled, irri-
table, and agitated while feeding. By 5 years, he could only
hold his head up, was severely spastic, had hyperreflexive
extremities, and was unable to eat solid foods. By 3 years
of age he was diagnosed with visual impairment due to
cortical abnormalities, with hypoplastic optic nerve and
fovea. Investigations demonstrated no lysosomal, per-
oxisomal or metabolic disorders. EEG demonstrated
supressed Grade 1 cerebral activity with generalized
abnormal cortical activity. MRI of spine demonstrated
no abnormalities; however, ventricles and sulci were
prominent in size and severely atrophic white and gray
matter (Figure 2B). He is presently 14 years old and
continues with generalized spasticity and requires a
pureed diet, which he regularly chokes on. He is less
irritable and on no medications.
Overall, all four children were products of an unre-
markable pregnancy, delivery and neonatal period. How-
ever, acquired microcephaly was noted within 2 monthsof birth. By 4 months of age, the infants displayed con-
stant irritability, regression of developmental milestones,
akathisia, increased startle response, spasticity, abnormal
tone, visual impairment and seizures. In two of the four
children, the anterior fontanelle had prematurely closed.
Brain imaging of all four affected children revealed a cha-
racteristic ventriculomegaly and progressive symmetrical
atrophy of brain matter—in particular the white and grey
matter of the cortex, sparing the infratentorial segments,
such as the midbrain, brainstem and cerebellum.
Based on the clinical findings and imaging, we named
this novel disorder as Autosomal Recessive Cerebral
Atrophy (ARCA).
Molecular investigations
Exome sequencing was performed on 2 affected indivi-
duals (V-10 and V-12) and a filtering method was ap-
plied to identify unique nucleotide variants, which
yielded 42 and 77 novel homozygous sequence variants
in individuals V-10 and V-12, respectively (Figure 3A).
Homozygosity mapping revealed a candidate region, the
homozygous block with the highest location score
(Figure 3B), encompassing 4.5 Mbp in chromosome 11q
with a location score of 303 comprising of 872 SNPs
and 91 genes (Figure 3B). Within this candidate re-
gion in chromosome 11, only 1 of the unique nucleotide
variants was present in homozygous state in both affected
individuals while their parents were obligate heterozy-
gotes. The variant is a C to T at c.995 in exon 10 of the
TMPRSS4 gene, resulting in an amino acid change from
threonine (T) to methionine (M) at residue 332 (T332M,
Figure 2 Coronal and sagittal views of T1-weighted MRI-head of ARCA patients demonstrating diffuse cortical atrophy and
ventriculomegaly. A) V-10 at 8 months of age, B) V-14 at 10 months of age.
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the pedigree is consistent with an autosomal recessive
inheritance pattern, and segregates with the ARCA
phenotype (see Additional file 1). The frequency of the
T allele was assessed within 208 Old Order Amish com-
munity members (excluding the pedigree). None had
the TT genotype while 12% had the CT genotype (car-
rier rate); thus 1 in 250 Old Order Amish are predicted
to have the TT genotype. In 2382 geographically and
ethnically diverse controls, all had the CC genotype
suggesting that the TT genotype is a private mutation
within this Old Order Amish community.
In silico investigations
To better understand the biological significance of this
mutation, various bioinformatics strategies were employed.
Residue 332 is within the trypsin-like serine protease
domain (Figure 5A). The ClustalW protein sequence align-
ment program showed strong conservation of this residue
among TMPRSS4 orthologs from other organisms
(Figure 5B). PolyPhen, Panther and SNPs3D, similarly
showed that the T to M change at residue 332 would be
deleterious or damaging to TMPRSS4 function.The crystal structure of TMPRSS4 has yet to be
published and there is no related structure with an
identity >40%. However, examination of the domain
structure of TMPRSS4 shows that the C-terminal half of
the protein is an excellent match (E-value of 3.1e-91) to
the trypsin-like serine protease family (cd00190) [5].
Alignment of the TMPRSS4 sequence with the available
structures of this family, using the Cn3D tool [6], de-
monstrate that residue 332 is in a conserved loop that
borders the active site. In majority of these homologous
structures, the residue side chain is partially exposed on
the surface and in one structure (1MKX) the side chain
is directed into the active site. In either case, the T332M
change—a polar to a non-polar amino acid coupled with
a longer side chain—would likely result in a steric clash
that could lead to substrate binding alteration and thus
altered TMPRSS4 function.
Discussion and conclusion
We describe a novel pediatric disorder in an Old
Order Amish community, named Autosomal Recessive
Cerebral Atrophy (ARCA) due to a progressive brain
atrophy leading to neurodegenerative symptoms
Figure 3 Genetic investigations to find the causative mutation for ARCA. A) Variant filtration of exome sequencing data of two affected
individuals, V-10 and V-12. Non-synonymous is defined as a change that alters the amino acid. B) Homozygosity mapping narrows candidate
region to 11q23.3, containing 91 genes.
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and loss of motor function.
Although there was slight variability in the age of
developmental milestone regression, by 4 months of age
all 4 infants displayed irritability, akathisia, increased
startle response, abnormal reflex and tone, visual impair-
ment, as well as seizures or seizure-like episodes. In
addition, the infants were noted to have microcephaly
early in life and brain imaging revealed a characteristic
ventriculomegaly and progressive symmetrical atrophy of
brain matter, particularly cortical white and grey matter.
Even though the degenerative process of the brain matter
most likely started earlier in development, the infants may
have been asymptomatic perinatally or during the neo-
natal stage, since the cerebrum is functionally silent du-
ring the early weeks of life [7]. It is likely that 2 of the 4
children continue to survive due to the level of medicalintervention provided by the caregivers rather than bio-
logical variability in the severity of the disease.
After conducting a comprehensive literature search of
the clinical descriptions of ARCA, we identified three
similar yet distinct syndromes. For instance, patients
with micropthalmia, brain atrophy (MOBA; MIM:
611222), develop extensive atrophy of white and grey
matter after 6 months of life leading to progressive spas-
ticity and seizures. However, unlike ARCA, MOBA pa-
tients also have congenital ocular malformations [8]. A
case report, in 2011, describes two Japanese sisters with
failure of postnatal brain growth with similar brain MRI
findings to those of ARCA-affected patients. However,
these sisters also had dysmorphic facial features
and simplified gyri that were not present in ARCA
[9]. Furthermore, West syndrome or Early Infantile
Epileptic Encephalopathy 5 (EIEE5, MIM: 613477) is
Figure 4 The genomic structure of TMPRSS4 gene consists of 13 coding exons with a nucleotide change in exon 10 (indicated in red)
that alters threonine to methionine at residue 332 (T332M). DNA sequence tracings of TMPRSS4 exon 10 in an ARCA affected (top), T332M
heterozygote (middle), and an unaffected (bottom) individual. For each tracing, the nucleotide sequence is shown at the top followed by the
single-letter amino acid code and codon numbers beneath.
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3 months of age due to brain atrophy [10]. However
this atrophy is mostly localized to the brainstem due
to hypomyelination of white matter in this region.
EIEE5 is due to a heterozygous mutation in SPTAN1
gene encoding spectrin, a cytoskeletal protein involved
in scaffolding [11].Figure 5 TMPRSS4 protein structure and amino acid sequence alignm
protein domain structure. At the N-terminal the protein has a transmembra
domain. The C-terminal encodes for the trypsin-like serine protease domain
serine). The T332 residue (indicated with a red star) is also found within thi
T332 residue (highlighted in red) is highly conserved across a representativUsing exome sequencing and homozygosity mapping
we identified a homozygous missense (T332M) muta-
tion in the serine protease, TMPRSS4. This mutation
segregated with the disease and no carriers were found
outside of the Amish community, giving genotypic and
statistical evidence that the TMPRSS4 mutation is likely
causative of ARCA. Bioinformatics further illustrated thatent with its orthologs. A) A schematic representation of TMPRSS4
ne domain, a LDL-receptor A domain, and a scavenger receptor
which contains the catalytic triad amino acids (histidine, aspartic acid,
s domain. B) Multiple alignments (using ClustalW) demonstrate that
e set of species-specific TMPRSS4 orthologs.
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protein function due to: 1) high evolutionary conservation
of the residue, 2) program predictions that demonstrate
pathological consequence, and 3) predicted changes in
protein structure leading to instability.
Serine proteases, such as trypsin-like proteases are
ubiquitously distributed and play pivotal roles in the
gastrointestinal, reproductive, and immune systems
[12]. Trypsin-like serine-proteases have been implicated
in brain plasticity, neural development, neurodege-
neration and neuroregeneration through human disor-
ders and knock-out zebra fish models [13]. Specifically,
one of the first serine proteases shown to be involved in
human non-syndromic mental retardation was neuro-
trypsin [14]. Of note, the family members of Type II
transmembrane serine proteases (TMPRSSs), TMPRSS2,
TMPRSS1, TMPRSS3, and TMPRSS5 have only been
implicated in certain types of sensorineural deafness [15].
TMPRSS4 is expressed in the gastrointestinal tract,
skeletal muscle and brain. It is highly expressed on the cell
surface of pancreatic, thyroid, lung, and other cancer
tissues, with potential biological implication in cell inva-
sion and migration [16].
This study demonstrates that TMPRSS4 is strongly
implicated in the causation of this autosomal recessively
inherited pediatric neurological disease. This informa-
tion can now be used for genetic counselling in the com-
munity and to stimulate mechanistic research on this
protein and mutation.
Additional file
Additional file 1: Figure of the pedigree illustrating ARCA
phenotype along with genotype data Figure legend (description)—
Sanger sequencing of TMPRSS4 c.995C>T in the pedigree is
consistent with an autosomal recessive inheritance pattern and
segregates with the ARCA phenotype. The top half of each symbol
indicates whether the individual is ARCA affected (black) or unaffected
(white). The bottom half of the symbol represents the genotype with T
shown in black and C shown in white.
Abbreviations
ARCA: Autosomal recessive cerebral atrophy; TMPRSS4: Transmembrane
protease, serine 4; SNP: Single nucleotide polymorphism; G-
tube: Gastrostomy tube; MELAS: Mitochondrial encephalomyopathy, lactic
acidosis, and stroke-like episodes; EEG: Electroencephalogram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PL and RAH were involved in design, acquisition and analysis of data, and
drafting of the manuscript. JW and JR were in involved acquisition and
analysis of data.LR, GBG, CAR, VMS, and DEB were involved in design,
acquisition and analysis of data, and made contributions to the draft of the
manuscript.
Acknowledgements
We acknowledge the generous cooperation of the families participating in
this study. We acknowledge the excellent technical assistance of Henian Caoand Roger Dewar. R.A.H. is a Career Investigator of the Heart and Stroke
Foundation of Ontario and holds the Edith Schulich Vinet Canada Research
Chair (Tier I) in Human Genetics and the Jacob J. Wolfe Distinguished
Medical Research Chair. P.L. was supported by the Canadian Institutes of
Health Research (CIHR) Scriver Family MD/PhD studentship award. This work
was supported by a team grant from the CIHR (CTP-79853, MOP-37854), the
Heart and Stroke Foundation of Ontario, Genome Canada through the
Ontario Genomics Institute, and grants from the Children’s Health Research
Institute, the Lawson Health Research Institute, and the Garrod Association.
Author details
1Robarts Research Institute, London, ON, Canada. 2Department of Pediatrics,
The Hospital for Sick Children, Toronto, ON, Canada. 3Departments of
Pediatrics, Biochemistry, Microbiology and Immunology, University of Ottawa
and Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON,
Canada. 4Department of Biochemistry, Schulich School of Medicine and
Dentistry, University of Western Ontario, London, ON, Canada. 5Department
of Pediatrics and Children’s Health Research Institute, Lawson Health
Research Institute, London, ON, Canada. 6Blackburn Cardiovascular Genetics
Laboratory, Robarts Research Institute, 100 Perth Drive, Room 406, London,
ON N6A 5K8, Canada.
Received: 14 June 2013 Accepted: 16 August 2013
Published: 17 August 2013
References
1. Rama-Devi R: Regression of milestones: neurodegenerative in 1st national
conference on neurogenetics. Pediatric Oncall 2006. [serial online] 2007
[cited 15 February 2007(Supplement 2)]; 4. Available from:
http: //www.pediatriconcall.com/fordoctor/Conference_abstracts/
NEUROGENETICSDEL/Approach.asp
2. Hardiman O, Doherty CP: Neurodegenerative Disorders: A Clinical Guide.
London: Springer; 2011.
3. Puffenberger EG, Hu-Lince D, Parod JM, Craig DW, Dobrin SE, Conway AR,
Donarum EA, Strauss KA, Dunckley T, Cardenas JF, et al: Mapping of
sudden infant death with dysgenesis of the testes syndrome (SIDDT) by
a SNP genome scan and identification of TSPYL loss of function.
Proc Natl Acad Sci U S A 2004, 101:11689–11694.
4. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix
choice. Nucleic Acids Res 1994, 22:4673–4680.
5. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK,
DeWeese-Scott C, Fong JH, Geer LY, Geer RC, Gonzales NR, et al: CDD: a
conserved domain database for the functional annotation of proteins.
Nucleic Acids Res 2011, 39:D225–D229.
6. Wang Y, Geer LY, Chappey C, Kans JA, Bryant SH: Cn3D: sequence and
structure views for Entrez. Trends Biochem Sci 2000, 25:300–302.
7. Verma UL, Archbald F, Tejani NA, Handwerker SM: Cerebral function
monitor in the neonate. I: normal patterns. Dev Med Child Neurol 1984,
26:154–161.
8. Kanavin OJ, Haakonsen M, Server A, Bajwa TJ, van der Knaap MS,
Stromme P: Microphthalmia and brain atrophy: a novel
neurodegenerative disease. Ann Neurol 2006, 59:719–723.
9. Hirose M, Haginoya K, Yokoyama H, Kikuchi A, Hino-Fukuyo N, Munakata M,
Uematsu M, Iinuma K, Kato M, Yamamoto T, Tsuchiya S: Progressive
atrophy of the cerebrum in 2 Japanese sisters with microcephaly with
simplified gyri and enlarged extraaxial space. Neuropediatrics 2011,
42:163–166.
10. Tohyama J, Akasaka N, Osaka H, Maegaki Y, Kato M, Saito N, Yamashita S,
Ohno K: Early onset West syndrome with cerebral hypomyelination and
reduced cerebral white matter. Brain Dev 2008, 30:349–355.
11. Saitsu H, Tohyama J, Kumada T, Egawa K, Hamada K, Okada I, Mizuguchi T,
Osaka H, Miyata R, Furukawa T, et al: Dominant-negative mutations in
alpha-II spectrin cause West syndrome with severe cerebral
hypomyelination, spastic quadriplegia, and developmental delay.
Am J Hum Genet 2010, 86:881–891.
12. Yousef GM, Kopolovic AD, Elliott MB, Diamandis EP: Genomic overview of
serine proteases. Biochem Biophys Res Commun 2003, 305:28–36.
13. Wang Y, Luo W, Reiser G: Trypsin and trypsin-like proteases in the brain:
proteolysis and cellular functions. Cell Mol Life Sci 2008, 65:237–252.
Lahiry et al. Orphanet Journal of Rare Diseases 2013, 8:126 Page 10 of 10
http://www.ojrd.com/content/8/1/12614. Molinari F, Rio M, Meskenaite V, Encha-Razavi F, Auge J, Bacq D, Briault S,
Vekemans M, Munnich A, Attie-Bitach T, et al: Truncating neurotrypsin
mutation in autosomal recessive nonsyndromic mental retardation.
Science 2002, 298:1779–1781.
15. Guipponi M, Toh MY, Tan J, Park D, Hanson K, Ballana E, Kwong D,
Cannon PZ, Wu Q, Gout A, et al: An integrated genetic and functional
analysis of the role of type II transmembrane serine proteases (TMPRSSs)
in hearing loss. Hum Mutat 2008, 29:130–141.
16. Liang B, Wu M, Bu Y, Zhao A, Xie F: Prognostic value of TMPRSS4
expression in patients with breast cancer. Med Oncol 2013, 30:497.
doi:10.1186/1750-1172-8-126
Cite this article as: Lahiry et al.: A mutation in the serine protease
TMPRSS4 in a novel pediatric neurodegenerative disorder. Orphanet
Journal of Rare Diseases 2013 8:126.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
